Protein predicts Gleevec resistance in gastrointestinal tumors

Excess amounts of a protein called IGF-1R in patients with gastrointestinal stromal tumors (GISTs) could indicate that the patient would be less responsive to the drug imatinib mesylate (known as Gleevec), according to Andrew K. Godwin, Ph.D., a researcher at the Fox Chase Cancer Center in Philadelphia.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news130154059.html">Protein predicts Gleevec resistance in gastrointestinal tumors</a></p> <p>Excess amounts of a protein called IGF-1R in patients with gastrointestinal stromal tumors (GISTs) could indicate that the patient would be less responsive to the drug imatinib mesylate (known as Gleevec), according to Andrew K. Godwin, Ph.D., a researcher at the Fox Chase Cancer Center in Philadelphia.</p>